Mar 11, 2020 8:00 am EDT Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico
Feb 13, 2020 9:00 am EST Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call
Feb 10, 2020 7:00 am EST Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre
Dec 23, 2019 8:31 pm EST Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
Nov 26, 2019 7:55 am EST Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia
Nov 18, 2019 8:38 am EST Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre’s Novel Mechanism of Action in Diabetes
Nov 13, 2019 7:55 am EST Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020